At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 15 enrolled
Drug / intervention
Methylnaltrexone Bromide 150 mg Oral Tablet +2 moredrug
Likely dose
Methylnaltrexone Bromide 150 mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Methylnaltrexone Versus Naloxegol in the Treatment of Opioid-Induced Constipation in the Emergency Department
In Brief
A Phase 4 clinical trial evaluating Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, and 1 other intervention for Constipation Drug Induced. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation Drug Induced
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartDec 2020
Primary CompletionMar 2023
TodayJul 2026
First PostedMay 14, 2018
Enrollment StartDec 23, 2020
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.1 years ago
Interventions
Methylnaltrexone Bromide 150 mg Oral Tabletdrug
Methylnaltrexone Bromide 150 mg Oral Tablet
Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1drug
Methylnaltrexone Bromide 12 MG Subcutaneous Solution
Naloxegol 25 MG Oral Tabletdrug
Naloxegol 25 MG Oral Tablet